Passage Bio Inc (PASG) - Total Liabilities
Based on the latest financial reports, Passage Bio Inc (PASG) has total liabilities worth $43.04 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Passage Bio Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Passage Bio Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Passage Bio Inc to evaluate short-term liquidity relative to the company's equity base.
Passage Bio Inc Competitors by Total Liabilities
The table below lists competitors of Passage Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fondia Oyj
HE:FONDIA
|
Finland | €4.19 Million |
|
Zelan Bhd
KLSE:2283
|
Malaysia | RM524.27 Million |
|
INFLECTION RESOURCES LTD.
F:5VJ
|
Germany | €318.29K |
|
National Tyre & Wheel Limited
F:N37
|
Germany | €267.74 Million |
|
Overactive Media Corp
V:OAM
|
Canada | CA$23.50 Million |
|
PeterLabs Holdings Bhd
KLSE:0171
|
Malaysia | RM21.70 Million |
|
Aelis Farma SA
PA:AELIS
|
France | €9.46 Million |
|
Daesung Microbiological Labs. Co. Ltd
KQ:036480
|
Korea | ₩22.56 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down Passage Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Passage Bio Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Passage Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Passage Bio Inc (2018–2024)
The table below shows the annual total liabilities of Passage Bio Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $41.15 Million | +4.81% |
| 2023-12-31 | $39.26 Million | -6.92% |
| 2022-12-31 | $42.18 Million | +15.83% |
| 2021-12-31 | $36.42 Million | +56.35% |
| 2020-12-31 | $23.29 Million | +446.66% |
| 2019-12-31 | $4.26 Million | -90.66% |
| 2018-12-31 | $45.63 Million | -- |
About Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galac… Read more